+91 44 2496 8000 info@caplinpoint.net

Completion of inspection by ANVISA-Brazil at the facility of Caplin Steriles Limited

This is to inform you that ANVISA- Brazil conducted an inspection of Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi. The inspection was conducted between August 12th and 16th, 2024 and concluded with zero observations. Chairman Mr.C.C.Paarthipan added “It is indeed gratifying to have two back to back audits with Zero observations. We…

Read More »

Caplin Point listed on Forbes Asia’s “200 Best Under a Billion” for 2024

Caplin Point Laboratories Ltd has been recognized yet again in Forbes Asia’s 200 Best Under a Billion list for the year 2024, a compilation that underscores companies’ sustained and robust performance across critical benchmarks. Carefully selected from a substantial pool of more than 20,000 publicly traded companies across the Asia-Pacific region, 200 enterprises with annual…

Read More »

Completion of Unannounced US FDA Inspection at the facility of Caplin Steriles Limited

This is to inform you that the United States Food and Drug Administration (US FDA) conducted an unannounced inspection of Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi. The inspection was conducted between August 5th and 9th, 2024 and concluded with zero observations. This outcome underscores the company’s strong commitment to maintaining the…

Read More »

CAPLIN STERILES GETS USFDA APPROVAL FOR TIMOLOL MALEATE OPHTHALMIC SOLUTION USP

Chennai, Aug 08, 2024: Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Timolol Maleate Ophthalmic Solution USP, 0.5% (Eye drops), a generic therapeutic equivalent version…

Read More »